Comparable stake leader
Alyeska Investment Group, L.P.
SEC ownership of Unity Biotechnology, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001463361.
Disclosed value leader
Alyeska Investment Group, L.P.
Comparable rows
1/16
Latest evidence
02 Apr 2025
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Alyeska Investment Group, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
1 of 16
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Alyeska Investment Group, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
02 Apr 2025
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001463361
- Issuer location
- South San Francisco, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Unity Biotechnology, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Alyeska Investment Group,...
Disclosed value leader
Alyeska Investment Group,...
Comparable rows
1/16
Latest evidence
02 Apr 2025
13D/G
3/4/5
Lead comparable stake: 9.2%
15 rows are not safely comparable across share classes.
13D/G row: Alyeska Investment Group, L.P.
Showing 1-8 of 16 holder rows.
Quick read
Alyeska Investment Group, L.P. leads the comparable SEC ownership view at 9.2%.
1 of 16 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Alyeska Investment Group, L.P.'s linked filing trail.
Comparable ownership
Top 1
Alyeska Investment Group, L.P.
9.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 16 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Alyeska Investment Group, L.P. |
13D/G
|
9.2%
|
$1,546,529
1,578,091 shares
|
$0 | 31 Mar 2025 |
| Anirvan Ghosh |
3/4/5
Chief Executive Officer, Director
|
—
mixed-class rows
|
$158,058
439,454 shares
mixed-class rows
|
— | 02 Apr 2025 |
| Jamie Dananberg |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
$114,955
62,817 shares
|
— | 31 Mar 2023 |
| Lynne Marie Sullivan |
3/4/5
CFO & Head of Corp. Dev.
|
—
mixed-class rows
|
$101,872
204,905 shares
mixed-class rows
|
— | 02 Apr 2025 |
| Alexander Hieu Nguyen |
3/4/5
CLO and Head of Ops
|
—
mixed-class rows
|
$50,216
121,753 shares
mixed-class rows
|
— | 02 Apr 2025 |
| Federico Grossi |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
—
150,000 shares
|
— | 06 Jan 2025 |
| Graham K. Cooper |
3/4/5
Director
|
—
class O/S missing
|
—
25,000 shares
|
— | 24 Jun 2021 |
| Kristina Burow |
3/4/5
Director
|
—
class O/S missing
|
—
25,000 shares
|
— | 24 Jun 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 04 Jul 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to Unity Biotechnology, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
Anirvan Ghosh
Net 12M change
$0
Latest report
27 Jun 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Anirvan Ghosh | Chief Executive Officer, Director | $158,058 | Filing P/S | 02 Apr 2025 | ||
| Jamie Dananberg | Chief Medical Officer | $114,955 | Mixed | 31 Mar 2023 | ||
| Lynne Marie Sullivan | CFO & Head of Corp. Dev. | $101,872 | Filing P/S | 02 Apr 2025 | ||
| Alexander Hieu Nguyen | CLO and Head of Ops | $50,216 | Filing P/S | 02 Apr 2025 | ||
| Nathaniel E. David | Director | Mixed | 21 Jun 2024 | |||
| Michael P. Samar | Director | Mixed | 21 Jun 2024 | |||
| Paul L. Berns | Director | Mixed | 21 Jun 2024 | |||
| Gilmore Neil O'Neill | Director | Mixed | 21 Jun 2024 | |||
| Margo R. Roberts | Director | Mixed | 21 Jun 2024 | |||
| Kristina Burow | Director | Mixed | 24 Jun 2021 | |||
| Keith R. Leonard | Director | Mixed | 21 Jun 2024 | |||
| Camille D. Samuels | Director | Mixed | 21 Jun 2024 | |||
| Craig R. Jalbert | President and Secretary, Director | Mixed | 27 Jun 2025 | |||
| Yehia Hashad | Director | Mixed | 08 Mar 2025 | |||
| Federico Grossi | Chief Medical Officer | Mixed | 06 Jan 2025 | |||
| Graham K. Cooper | Director | Mixed | 24 Jun 2021 |
Recent insider transactions for Unity Biotechnology, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.